Network meta-analysis indirectly compares efficacy, safety of next-generation inhibitors.
Multinational phase 4 study.
Meta-analysis finds risk significantly elevated only with use for more than a year.
Exploratory analyses identify potential biomarkers.
Final OS analysis of the phase 3 double-blind ARAMIS study.
Secondary analysis of randomized trial supports NCCN recommendations.
Final OS analysis of phase 3 double-blind SPARTAN study.
Safer procedure with advances in robotic surgery may have contributed to increasing trend.
Retrospective study reported similar pathologic and long-term oncologic outcomes.
Some men can have longer follow-ups.
Additional follow-up data from phase 3 CA184-043 study.
TRITON2 study shows good tolerability.
Ten-year results of the Prostate testing for cancer and Treatment (ProtecT) trial.
A systematic review of 45 studies report variability in threshold levels.
Additional pelvic lymph node irradiation does not lead to clinically meaningful increases in IMRT patient-reported toxicity.
Late dosing increases mean testosterone levels.
Data presented at the virtual American Urological Association 2020 annual meeting.
